AR and prostate cancer: Enzalutamide in combination with radiation therapy has been shown to decrease the survival of AR-positive LNCaP cells in vitro, but the treatment had no effect on AR-negative PC-3 prostate cancer cells [19], suggesting that the enzalutamide-related radiosensitization in LNCaP cells is mediated via AR.